Venture Life Group PLC Key oral care brand - clinical trial on COVID-19 (8936W)
24 Agosto 2020 - 8:00AM
UK Regulatory
TIDMVLG
RNS Number : 8936W
Venture Life Group PLC
24 August 2020
24 August 2020
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Group")
Venture Life's leading oral care brands participation in UK
clinical trial on COVID-19 patients
Venture Life (AIM: VLG), a leader in developing, manufacturing
and commercialising products for the self-care market, announced on
15 May 2020 that it supported further research into the idea that
using mouthwash could reduce the transmission of enveloped viruses
such as COVID-19. Today the Company announces its involvement in a
UK-led clinical trial on COVID-19 patients, in partnership with
Cardiff University. This independent multi-centre clinical study,
which is being led by Professor David Thomas at Cardiff University,
will investigate the possibility that using over-the-counter
mouthwashes could help to reduce the viral load and therefore the
transmission of COVID-19 in the mouth. Venture Life is delighted to
confirm that its leading mouthwash, Dentyl, will be involved in
this UK clinical trial.
A literature review of previous research led by Professor
Valerie O'Donnell at Cardiff University and expert input from a
group of virologists, microbiocide experts, lipid specialists and
healthcare experts from the universities of Cardiff, Nottingham,
Ottawa and Barcelona, published in May 2020, suggested the
possibility that certain mouthwashes could be used to help reduce
transmission of enveloped viruses such as SARS-CoV2, but that more
research was needed to test this idea. The review concluded that
Cethylpyridinium Chloride (CPC) may be effective in this respect.
Venture Life's Dentyl mouthwash, which is currently sold in the UK
and eleven other countries, contains CPC as its main active
ingredient.
Venture Life is delighted to be partnering with Cardiff
University and its affiliates, in order to help facilitate this
valuable research. The clinical study entitled 'The measurement of
mouthwash anti-viral activity against COVID-19' (MOMA) will be
commencing in August and is expected to last for 12 weeks. This is
a multi-centre study and will recruit patients currently in
hospital with COVID-19, commencing at Cardiff hospital.
Professor David Thomas from Cardiff University commented: "We
are very keen to start this much needed clinical trial as our
review of the literature indicated that we need to look deeper into
the possible positive impact that mouthwashes may play on the
transmission of COVID-19. We believe this is an exciting
opportunity to determine whether a compound that can inactivate an
enveloped virus in a test tube may work in humans, actively
shedding the virus in the mouth and throat'.
Jerry Randall, CEO of Venture Life, commented: "We are the only
mouthwash manufacturer to be involved in the Cardiff University
clinical study on COVID-19 patients; we are delighted to support
this independent study to further explore the initial findings that
CPC may reduce the viral load and therefore the possible
transmission of COVID-19. Our Dentyl mouthwash, which uses CPC as
its main antibacterial agent, has been developed by dentists and is
recommended by dentists to reduce plaque in the mouth, and is very
effective at this. We are excited at the prospect that this long
standing, well known mouthwash product could help in the fight
against COVID-19."
Link to initial research paper:
https://academic.oup.com/function/article/1/1/zqaa002/5836301
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Andrew Waters, Chief Financial Officer
Cenkos Securities plc (Nomad and Joint Broker) +44 (0) 20 7397
8900
Stephen Keys / Mark Connelly / Cameron MacRichie (Corporate
Finance)
Russell Kerr / Michael Johnson (Sales)
N+1 Singer (Joint Broker)
Shaun Dobson / Carlo Spingardi +44 (0) 20 7496 3000
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in the UK, The
Netherlands and Italy, the Group's product portfolio includes some
key products such as the UltraDEX and Dentyl oral care product
ranges, food supplements for maintaining brain function, medical
devices for women's intimate healthcare, fungal infections and
proctology, and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK and The Netherlands
these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDDBGDICDDDGGX
(END) Dow Jones Newswires
August 24, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Apr 2023 a Apr 2024